CION Ameerpet
If lung cancer has been found or suspected, your team needs to know the exact gene changes driving it — because those details decide which targeted therapy or immunotherapy can work. A liquid biopsy is a simple blood test that can read some of those changes from circulating tumour DNA (ctDNA), without another tissue procedure. This guide explains, in plain language, what a liquid biopsy for lung cancer is, how the blood test finds a lung cancer mutation, when it is used, and how it sits alongside a tissue biopsy — so you can make decisions calmly and well-informed.
A liquid biopsy is a blood test that looks for signs of cancer in your bloodstream, rather than in a piece of tissue. When lung cancer cells grow and turn over, they shed tiny fragments of their DNA into the blood. These fragments are called circulating tumour DNA, or ctDNA. A liquid biopsy reads that ctDNA in a sample taken from a vein in your arm — the same way an ordinary blood test is done.
What makes this useful is not just detecting that cancer DNA is present, but reading the specific gene changes it carries. Modern lung cancer care depends on knowing the precise mutation — because a tumour driven by an EGFR change, an ALK rearrangement, or a ROS1 change is often treated with a tablet aimed at that exact target, not with general chemotherapy alone.
A liquid biopsy is sometimes called a blood test for a lung cancer mutation, a ctDNA lung cancer test, or circulating tumour DNA testing. They all describe the same idea: finding and reading cancer DNA in the blood, so your team can match the treatment to the tumour.
A liquid biopsy does not replace the conversation with your doctor, and a single blood test rarely tells the whole story on its own. It is one tool that works best alongside your scans, your symptoms, and — in many cases — a tissue biopsy. Used well, it can speed up the path to the right treatment without an extra procedure.
Because it is a blood test, a liquid biopsy is straightforward for you — the careful work happens in the laboratory afterwards. Here is what usually happens, in order.
A nurse takes a sample of blood from a vein in your arm into special tubes. You usually do not need to fast, and the draw itself feels like any routine blood test — a brief pinch, then it is done.
In the laboratory, the blood is processed to separate out the cell-free DNA floating in the plasma. Within this is the small amount of circulating tumour DNA — the ctDNA — that came from the cancer.
Sensitive molecular techniques scan the ctDNA for specific gene changes known to drive lung cancer — for example EGFR, ALK, ROS1, and others. Many liquid biopsies test for a whole panel of targets at once.
The laboratory prepares a report listing which gene changes were found, if any. Your oncologist reads this alongside your scans and any tissue result to decide what it means for you.
You sit with your specialist to talk through the result in plain language. If a treatable target is found, a matched therapy can be discussed. If the blood test is negative, a tissue biopsy may still be advised to be sure.
Major guidelines now recommend testing every patient with advanced non-small cell lung cancer for a panel of treatable gene changes — and a liquid biopsy can sometimes deliver that answer faster than a repeat tissue biopsy, because it only needs a blood draw. One important caveat: a negative blood test does not rule a mutation out, since not every tumour sheds enough ctDNA into the blood; in that situation a tissue biopsy is still needed. (Sources: NCCN; College of American Pathologists / IASLC / AMP molecular testing guidance.)
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
A short, doctor-led conversation can replace days of anxious searching. We walk this journey with you, from the first question onward.
A liquid biopsy is most useful when your team needs to know the tumour's gene changes but a tissue sample is hard to obtain or insufficient. A spot may be in a difficult place to reach, a previous biopsy may not have collected enough tissue for full molecular testing, or your overall health may make another procedure less ideal. In these situations, a blood test for a lung cancer mutation can offer an answer without another needle into the lung.
It is also used to monitor treatment over time. In some people on targeted therapy, the cancer eventually finds a way around the medicine by developing a new mutation. A repeat ctDNA lung cancer test can sometimes pick up that resistance change from a blood sample, helping your team decide whether to switch to a different targeted drug.
Whether a liquid biopsy, a tissue biopsy, or both is right for you is an individual decision. Your specialist weighs where the cancer is, how much tissue is already available, how quickly an answer is needed, and what each test can and cannot tell you — and explains that reasoning so the plan makes sense to you.
A liquid biopsy and a tissue biopsy are not rivals; they answer questions in different ways and often work best together. Here is an honest, balanced look at the strengths and limits of each.
No needle into the lung and no procedure risks such as a small air leak. This makes it gentler when another procedure would be difficult or when a quick answer is needed.
Because it only needs blood, a liquid biopsy can sometimes return key gene results sooner than arranging and reporting a fresh tissue biopsy — useful when treatment decisions are time-sensitive.
Not every tumour sheds enough ctDNA into the blood. So a negative liquid biopsy does not rule out a mutation — a tissue biopsy is then needed to be sure.
Examining actual tumour tissue confirms the cancer type under the microscope and supports the fullest molecular testing. It remains the standard when tissue can be safely obtained.
In practice the two are complementary. A team may start with one and add the other, so that no treatable target is missed and the plan rests on the clearest possible picture.
Which test, or both, depends on where the cancer is, how much tissue exists already, how urgently an answer is needed, and your overall health — discussed openly with you.
If the blood test finds a treatable gene change — for example an EGFR mutation, an ALK rearrangement, or a ROS1 change — it can open the door to a targeted therapy, often a tablet aimed precisely at that change. These matched treatments can work very differently from general chemotherapy, which is exactly why finding the right mutation matters so much.
If the liquid biopsy is negative, it does not mean there is no mutation. It may simply mean the tumour did not shed enough ctDNA into the blood at that moment. In that case your team will usually advise a tissue biopsy to test the tumour directly, so a treatable target is not missed. A negative blood test is a reason to look further, not a reason to stop.
Whatever the result, the report is never read in isolation. Your oncologist interprets it alongside your scans, your tissue findings, and your symptoms, then explains in plain language what it changes and what it does not. No result is shared in a rush, and every finding is discussed with time for your questions.
Choosing between a liquid biopsy and a tissue biopsy — or using both — is a decision that should never rest on a single opinion. At CION, your testing and treatment plan is reviewed by a tumour board, a panel of medical, surgical, and radiation oncologists who agree the path together, so the choice is considered from every angle.
You sit with a doctor for a 45-minute consultation, with unhurried time to ask what each test can and cannot tell you. We order tests step by step and explain each one — no unnecessary tests, and transparent costs from the start. Our team brings 150+ years of combined experience and 17 super-specialist oncologists across 35+ centres in Telangana and Andhra Pradesh, having cared for 15,000+ patients.
Whether your result points to a matched targeted therapy or to further testing, you have a team that walks this journey with you, making decisions for your healing, not for billing. To understand the wider picture, see our overview of lung cancer at CION, read about the lung cancer diagnosis pathway, compare it with a CT-guided lung biopsy, or explore lung cancer treatment in Hyderabad.
Patients across Telangana and Andhra Pradesh share what it felt like to be heard, examined unhurriedly, and guided with honesty at CION.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.A liquid biopsy is a blood test that looks for signs of cancer in your bloodstream instead of in a piece of tissue. When lung cancer cells grow and turn over, they shed tiny fragments of their DNA into the blood; these fragments are called circulating tumour DNA, or ctDNA. A liquid biopsy reads that ctDNA from a sample taken from a vein in your arm. The most valuable part is not just detecting cancer DNA, but reading the specific gene changes it carries — such as EGFR, ALK, or ROS1 — because those details decide which targeted therapy could work. It is sometimes called a blood test for a lung cancer mutation, a ctDNA test, or circulating tumour DNA testing. It is one tool that works best alongside your scans and, in many cases, a tissue biopsy.
After a routine blood draw, the laboratory separates out the cell-free DNA floating in the plasma. Within this is a small amount of circulating tumour DNA — ctDNA — that came from the cancer. Sensitive molecular techniques then scan that ctDNA for specific gene changes known to drive lung cancer, such as EGFR, ALK, and ROS1. Many liquid biopsies test for a whole panel of targets at once. The laboratory prepares a report listing which changes were found, if any, and your oncologist reads this alongside your scans and any tissue result. Because the cancer DNA is present only in tiny amounts, the test relies on very sensitive technology to find it reliably.
ctDNA stands for circulating tumour DNA. As cancer cells grow and break down, they release small fragments of their DNA into the bloodstream, where it mixes with the normal cell-free DNA that everyone has. A ctDNA lung cancer test is a liquid biopsy that isolates and reads these tumour fragments to look for the gene changes driving the cancer. The amount of ctDNA varies from person to person and over time, which is one reason a blood test does not always pick up a mutation that is present. When ctDNA is detected and shows a treatable change, it can guide your team straight to a matched targeted therapy.
A liquid biopsy and a tissue biopsy answer questions in different ways. When a liquid biopsy finds a treatable gene change, that result is generally reliable and can be acted on. The key difference is what a negative result means: not every tumour sheds enough ctDNA into the blood, so a negative liquid biopsy does not rule out a mutation. A tissue biopsy examines actual tumour tissue under the microscope and supports the fullest molecular testing, which is why it remains the reference standard when tissue can be safely obtained. In practice the two are complementary — a team may start with one and add the other so that no treatable target is missed.
A liquid biopsy is most useful when the tumour is hard to reach, when a previous biopsy did not collect enough tissue for full molecular testing, or when your overall health makes another procedure less ideal. In these situations a blood test for a lung cancer mutation can offer an answer without another needle into the lung. It is also used to monitor treatment over time, because some cancers on targeted therapy develop a new resistance mutation that a repeat ctDNA test can sometimes detect. Whether a liquid biopsy, a tissue biopsy, or both is right for you is an individual decision your specialist makes based on where the cancer is, how much tissue is already available, and how quickly an answer is needed.
A negative liquid biopsy means no treatable gene change was detected in the blood at that time — but it does not prove there is no mutation. The tumour may simply not have shed enough ctDNA into the bloodstream for the test to read it. For that reason, a negative blood test is usually a reason to look further, not to stop. Your team will commonly advise a tissue biopsy to test the tumour directly, so a treatable target is not missed. This step-by-step approach is normal and is done to make sure your treatment plan rests on the clearest possible information, not on an incomplete picture.
The test itself is just a blood draw from a vein in your arm, so it feels like any routine blood test — a brief pinch, then it is done. You usually do not need to fast or do any special preparation. The careful work happens afterwards in the laboratory. How long results take depends on the panel of gene changes being tested and the laboratory, but molecular results from a liquid biopsy can sometimes come back sooner than arranging and reporting a fresh tissue biopsy. Your team will tell you when to expect the report and will explain the result in plain language, alongside your scans, with time for your questions.
A liquid biopsy can look for the gene changes that guide modern lung cancer treatment, including EGFR mutations, ALK rearrangements, ROS1 changes, and several others, depending on the panel ordered. These are the targets that may be matched to a specific tablet aimed precisely at that change, rather than general chemotherapy. Major guidelines now recommend testing every patient with advanced non-small cell lung cancer for such treatable targets, and a liquid biopsy is one way to do that. Exactly which changes your test looks for depends on the laboratory and the panel your oncologist selects, which is chosen to fit your situation and discussed with you beforehand.
Browse our complete library of lung cancer guides — symptoms, types, diagnosis, stages, treatment and living with lung cancer.